10-Q: Catheter Precision Reports Q1 2025 Results, Cites Going Concern Uncertainty

Catheter Precision's Q1 2025 results reveal increased revenue offset by higher expenses, leading to a net loss and raising concerns about the company's ability to continue as a going concern.

Summary

• Catheter Precision, Inc. reported its financial results for the first quarter of 2025.
• The company's revenue increased to $143 thousand, compared to $82 thousand in the same period last year.
• However, operating expenses also increased, leading to an operating loss of $3.575 million.
• The net loss for the quarter was $4.045 million, or $0.36 per share, compared to a net loss of $2.675 million, or $3.60 per share, in Q1 2024.
• The company acknowledges substantial doubt about its ability to continue as a going concern within the next 12 months due to recurring losses and negative cash flows.
• Management plans to raise additional capital through public or private equity or debt financing.
• The company completed an asset acquisition of Perikard, LLC in January 2025, and Cardionomic in May 2025.
• A private placement was entered into in May 2025, raising $1.5 million in cash and securing Convertible Promissory Notes of QHSLab, Inc.

Sentiment

Score: 3

Explanation: The document presents a mixed picture, with increased revenue offset by a larger net loss and concerns about the company's ability to continue as a going concern. The need for additional funding and the presence of material weaknesses in internal control contribute to a negative sentiment.

Positives

• Revenue increased by approximately 74% compared to the same period last year, driven by LockeT sales.
• The company completed strategic asset acquisitions to expand its product portfolio.
• The company secured additional funding through a private placement in May 2025.

Negatives

• The company incurred a net loss of $4.045 million in Q1 2025.
• Operating expenses increased, contributing to the larger net loss.
• The company has an accumulated deficit of $296.4 million and only $0.5 million in cash and cash equivalents as of March 31, 2025.
• There is substantial doubt about the company's ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is dependent on raising additional funding.
• Failure to secure additional financing could force the company to reduce operations or seek relief from creditors.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company's future success depends on the acceptance of its products by hospitals, physicians, and patients.
• The company faces intense competition in the medical device industry.

Future Outlook

The company expects operating losses and negative cash flows to continue for the foreseeable future and is actively seeking additional funding through public or private equity or debt financing.

Management Comments

• Management estimates that based on the Company's liquidity resources, there is substantial doubt about the Company's ability to continue as a going concern within 12 months from the date of issuance of the unaudited condensed consolidated financial statements.
• Management plans to raise additional capital through public or private equity or debt financing to fulfill its operating and capital requirements for at least 12 months from the date of the issuance of the unaudited condensed consolidated financial statements.

Industry Context

The medical device industry is highly competitive, and Catheter Precision faces competition from companies with greater resources. The company's success depends on its ability to innovate and commercialize new products, as well as navigate regulatory hurdles and secure reimbursement for its products.

Comparison to Industry Standards

• It is difficult to compare Catheter Precision's results directly to industry standards due to its unique product portfolio and stage of development.
• Comparable companies in the cardiac electrophysiology space include larger, more established players like Biosense Webster (Johnson & Johnson), Abbott, and Medtronic, which have significantly greater resources and broader product offerings.
• Smaller, emerging growth companies in the medical device sector often face similar challenges related to funding, regulatory approvals, and market adoption.
• Given the limited revenue and significant net losses, Catheter Precision's financial performance is below the average of established industry leaders.
• The company's ability to secure additional funding and achieve commercial success with its VIVO System and LockeT device will be critical to its long-term viability.

Related Party Transactions

• David A. Jenkins and his affiliates held approximately $25.1 million of Old Catheters Convertible Promissory Notes that were converted into 7,856.251 shares of Series X Convertible Preferred Stock in connection with the Merger.
• Mr. Jenkins and his affiliates also received royalty rights equal to approximately 12% of the net sales, if any, of LockeT, commencing upon the first commercial sale and through December 31, 2035, in consideration for forgiving the interest accrued but remaining unpaid under the Notes in an aggregate amount of approximately $13.9 million.
• Mr. Jenkins daughter, the Companys non-executive Chief Operating Officer, received options to purchase 14,416 shares of the Companys common stock upon the closing of the Merger in exchange for her options to purchase shares of Old Catheter common stock, converted based on the exchange ratio in the Merger.
• During the year ended December 31, 2024, the Company entered into various short-term promissory notes with various related parties (the Related Party Notes).
• On September 3, 2024, the Jenkins Family Charitable Institute also invested approximately $500,000 in the Companys public offering and received 265,000 shares of common stock; 235,000 pre funded warrants with an exercise price of $0.0001 and no expiration date; 500,000 Series H Warrants with an exercise price of $1.00 per share that expired on March 3, 2025; 500,000 Series I Warrants with an exercise price of $1.00 per share that expire on March 3, 2026; and 500,000 Series J Warrants with an exercise price of $1.00 per share that expire on September 3, 2029.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees face uncertainty due to the company's going concern status.
• Customers may be concerned about the company's ability to continue providing products and services.
• Suppliers and creditors face increased risk of non-payment.

Next Steps

• The company plans to raise additional capital through public or private equity or debt financing.
• The company will continue to monitor its operating costs and seek to reduce its current liabilities.
• The company will continue to undertake the required research, development, and commercialization activities for the purchased assets.
• The company will monitor the effectiveness of its remediation plans and will make changes management determines to be appropriate to eliminate the disclosed material weaknesses.

Key Dates

Keywords

Catheter Precision, financial results, going concern, VIVO System, LockeT, asset acquisition, private placement, net loss, revenue, medical devices, cardiac electrophysiology